Anixa Biosciences Earns Canadian Patent Allowance for AMHR2 Ovarian Cancer Vaccine Technology
ANIX•Anixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for its AMHR2-targeted ovarian cancer vaccine patent, expanding its international IP protection beyond its July 2025 U.S. patent. The patent covers administering a nucleic acid encoding the AMHR2 polypeptide to elicit an immune response for ovarian cancer prevention or treatment.
1. Canadian Patent Approval
The Canadian Intellectual Property Office issued a Notice of Allowance for Anixa’s ovarian cancer vaccine patent, marking a significant extension of the company’s intellectual property rights into Canada. This allowance reinforces Anixa’s position in international markets and protects its proprietary AMHR2-targeted immunoprevention technology.
2. AMHR2 Vaccine Patent Scope
Licensed exclusively from Cleveland Clinic, the allowed patent covers methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide. These claims define the process by which the vaccine elicits an AMHR2-specific immune response to prevent or treat ovarian cancer in high-risk populations.
3. Strategic Expansion of IP
This Canadian patent allowance complements the U.S. patent granted in July 2025, broadening Anixa’s global IP estate around its ovarian cancer vaccine. The expanded protection supports the company’s strategy to build a comprehensive cancer vaccine platform and underpins future clinical, regulatory, and partnership opportunities.
